

October 11, 2005

Suzuken Co., Ltd.

Yoshiki Bessho, President and CEO

Stock Code: 9987

Stock Exchange Listing: Tokyo, Nagoya, and Sapporo Stock Exchanges

Contact: Takahito Ito, Director, Senior Executive Officer,

Senior General Manager, Corporate Planning Headquarters

Tel.: +81-52-961-2331

**Approval Received to Manufacture and Sell Seibule (Miglitol), an Agent
for Treating Postprandial Hyperglycemia in Type 2 Diabetes Mellitus**

Sanwa Kagaku Kenkyusho Co., Ltd., a subsidiary of Suzuken Co., Ltd., has announced that today it obtained approval from the Ministry of Health, Labour and Welfare to produce and sell Seibule (Miglitol), an agent for treating postprandial hyperglycemia in Type2 diabetes mellitus, in 25mg, 50mg, and 75mg tablets.

Following inclusion in the National Health Insurance (NHI) price listing, the drug will be sold under the brand names "Seibule 25mg," "Seibule 50mg," and "Seibule 75mg." The products will be co-promoted with Dainippon Sumitomo Pharma Co., Ltd.

Seibule is an oral medication that delays the digestion of carbohydrate with the alpha-glucosidase inhibition, thereby improving postprandial hyperglycemia. In particular, it acts quickly to effectively suppress the rapid rise in blood glucose that occurs within one hour of eating and reduces the secretion of insulin from the pancreas. Seibule promises to make a significant contribution to the treatment of the estimated 7.4 million diabetics in Japan.

Developed by German company Bayer HealthCare AG, Miglitol has been approved for use in 29 countries overseas, mainly in Europe and North America. In Japan, Bayer Yakuhin, Ltd. handled development activities up to phase II clinical trials, after which Sanwa acquired the license to develop the drug.

An outline of Seibule is as follows.

Effectiveness

Improves postprandial glycemia in type 2 diabetes patients (prescription is limited to patients who have not benefited sufficiently from dietary and exercise regimens or taking sulfonylurea in combination with dietary and exercise regimens).

Dosage

Normally, adults should take 50mg of Miglitol orally three times a day at a start of each meal. If the effects are insufficient, the dosage can be increased to 75mg under close observation of the healthcare provider.